

Oxford Immunotec Global PLC  
Form 8-K  
January 07, 2019

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (date of earliest event reported): January 7, 2019**

---

**OXFORD IMMUNOTEC GLOBAL PLC**

**(Exact name of registrant as specified in its charter)**

---

**England and Wales**

**(State or other jurisdiction**

**of incorporation)**

**001-36200      98-1133710**  
**(Commission   (IRS Employer**  
**File Number)   Identification No.)**

**94C Innovation Drive, Milton Park, Abingdon OX14 4RZ, United Kingdom**

**(Address of principal executive offices)**

**Registrant's telephone number including area code +44 (0) 1235 442780**

---

Check appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

**Item 8.01 Other Events.**

On January 7, 2019, in advance of a public webcast presentation at the J.P. Morgan Healthcare Conference on January 9, 2019, Oxford Immunotec Global PLC (the “Company”) released an investor presentation (the “Investor Presentation”). A copy of the Investor Presentation is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The Investor Presentation is accessible via a link posted on the Investors, Events & Presentations section of the Company’s website: [www.oxfordimmunotec.com](http://www.oxfordimmunotec.com).

---

**Item 9.01 Financial Statements and Exhibits.**

**(d) Exhibits**

<b>Exhibit Number</b>	<b>Exhibit Description</b>
99.1	<u>Investor Presentation</u> <u>JP Morgan Healthcare Conference 2019</u>

**Signatures**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 7, 2019

**OXFORD  
IMMUNOTEC  
GLOBAL PLC**

By: /s/  
Richard  
M. Altieri  
Richard  
M. Altieri  
Chief  
Financial  
Officer

